3i?)-3-amino-2-hydroxy-4-phenylbutyric acid ((2S,3R)-AHPA) was examined. OH-Ubenimex was almost identical in inhibitory activity against mouse peritoneal resident macrophage aminopeptidases (APases) and the growth of IMCcarcinoma in mice to ubenimex. In contrast, the inhibition of; mousespleen cell APase activities in vitro, blastogeneses of mouse T and B cells in vitro, delayed cutaneous hypersensitivity in mice, and the growth of C1498 leukemia and HeLaS3 cells in vitro was weaker than ubenimex. MacrophageAPase activity was only slightly inhibited by (2S,3R)-AHPA which also had practically no activity in the other biological assays.
Ubenimex, ( -)-Af-[(2£,3i?)-3-amino-2-hydroxyphenylbutyryl]-L-leucine, is a dipeptide discovered in the culture filtrate of Streptomyces olivoreticuli1^and can inhibit aminopeptidase (APase) activities2~4) and cause immunomodulation5~14:>.
Ubenimex also has antitumor activities6'11'15'16-1 together with enhancing the effects of antitumor activities of other cytotoxic agents170. It is believed that ubenimex interacts with membrane bound APases to activate macrophages and T cells18). About 107 and 106 molecules of ubenimex bound to each of these cell types19). Recently, two main metabolites, (-)-iV-
and (2S,3iQ-3-ammo-2-hydroxy-4-phenylbutyric acid ((2S,3iO-AHPA), were identified in human urine20).
In the present study we examined whether these metabolites retain any biological activity.
Materials and Methods

Chemicals
Ubenimex, OH-ubenimex and (IS^RyAHFA were kindly synthesized by Dr. Saino, Research Laboratories, Nippon Kayaku Co., Ltd., as reported previously21>22). Concanavalin A (Con A) was purchased from Pharmacia Fine Chem., Inc. and lipopolysaccharide of Escherichia coli 055 ; B5 (LPS) from Difco Lab. L-Arginine-/3-naphthylamide (Arg-NA), L-leucine-/3-NA (Leu-NA) and L-phenylalanine-/3-NA (Phe-NA) were obtained from Sigma Chemical Co. Oxazolone (4-ethoxymethylene-2-oxazolone-5-one) was purchased from Aldrich Chemical Co., Ltd. [6-3H]Thymidine ([3H]TdR) with a specific activity of 15.5 Ci/mmol was obtained from NewEngland Nuclear. Animals Specific pathogen free inbred BALB/c, C57BL/6 and CD(BALB/c XDBA/2)F1 mice were obtained from Charles River Japan, Inc. These mice were 8 to 10 weeks old and housed here in an By recommendation of WHO, the name of ubenimex is used for bestatin.
Isorack with a clean air system. Each group consisted of at least 5 mice.
Tumors
Myeloid leukemia C1498 and IMC carcinoma have been maintained in ascites form in C57BL/6 mice and CDF1mice, respectively. HeLa S3 cell line was maintained as monolayers in Eagle's minimumessential medium (MEM) supplemented with 10 % fetal bovine serum (FBS; Gibco Island, NY), MEM non essential amino-acid, streptomycin and benzylpenicillin. Kato III cell and K562cell lines were maintained in Rosewell Park Memorial Institute (RPMI) 1640 mediumsupplemented with 10%FBS.
Cell Preparation
Spleen cells were prepared as described previously15-*. T cells were separated from the spleen cells by passing through a Nylon column. Resident macrophages were washed out from the mouse peritoneal cavities with Hanks' balanced salt solution (HBSS), Enzvme Inhibition APase activity was measured as reported previously4) by measuring /3-naphthylamine liberated from amino acid-NA after incubation. Briefly, HBSScontaining amino acid-NA and an enzyme source was incubated for 30 minutes at 37°C and then cooled to 0°C to terminate the reaction. The liquid phase of the mixture was separated by centrifugation, heated for 5 minutes on boiling water and subjected to fluorescence spectrophotometry. APase activity was calculated from the amount of /3-naphthylamine formed by the added enzyme.
Blastogenesis
Spleen T cells or unseparated spleen cells were used for testing T cell or B cell blastogenesis, respectively. Both cell types were incubated in microplates in the presence of an optimal concentration of Con A and LPS. Cultures were set up in triplicate. Each well contained 1 x 105 cells in a volume of 0.2 ml of RPMI1640 supplemented with 20% of FBS and antibiotics.
After 48 hours of incubation at 37°C cultures were pulsed with 1 fid [3H]TdR per well and the cells collected 6 hours later.
DCHto Oxazolone
Delayed cutaneous hypersensitivity (DCH)to oxazolone was tested as described previously23).
BALB/cmice were sensitized by painting on the shaved abdomens with 0.1 ml of 5%oxazolone in absolute ethanol. Three days later the sensitized mice were challenged by painting a hind footpad with the same oxazolone solution. DCHwas evaluated 24 hours after the challenge by measuring the thickness of the footpad with calipers. Antitumor Effect HeLa S3, Kato III and K562 cells were cultured at the initial density of 5 x 104 cells/2 ml/plate. Four hours after incubation of Kato III and K562 cells or 48 hours after incubation ofHeLa S3 cells, ubenimexor ubenimexmetabolites were added at various concentrations and cultured for a further 3 days. The cell numbers before and after treatment were counted by a coulter counter (model ZB1). The IC50 value, which is the concentration of each sample required for 50% inhibition of growth, was obtained graphically by a plot of its log concentration versus the probit of inhibition rate. Antitumor effects against mousesyngeneic tumor, IMCcarcinoma and C1498leukemia in mice were also examined as described previously15). The effect of ubenimex administration was evaluated by comparing the average tumor weight in treated mice with that of non-treated mice 20 days after tumor inoculation.
Results
We examined the effects of two ubenimex metabolites, OH-ubenimex and (2S,3iQ-AHPA, on the APase activity of peritoneal resident macrophages and spleen cells (Table 1) . Consistent with previous reports45, ubenimex inhibited the Arg-NA, Leu-NAand Phe-NA hydrolyzing activities of both The incubation was done in HBSS including 2 x 106 spleen cells from female BALB/c mice with an age of 9 weeks or 2 x 105 macrophages from the same mice in a total volume of 1.0ml. Arg-NA, Leu-NA or Phe-NA was added at 0.05 him as the substrate. IC30 value means the concentration of each sample required for 30% inhibition of the enzvme activity. immunocompetent cells. OH-Ubenimex also inhibited these three macrophage activities, and the Arg-NA hydrolyzing activity of spleen cells to almost the same extent as ubenimex. However, the inhibition of the Leu-NA and Phe-NA hydrolyzing activities of spleen cells was weaker than that of ubenimex. (25,3i^)-AHPA inhibited the Phe-NA hydrolyzing activity of spleen cells to a similar extent as OH-ubenimex but had practically no inhibitory activity on the other amino acid-NA hydrolyzing activities examined.
The effects of OH-ubenimex and (2S,3R)-AHPAon three immunefunctions, that is, T and B cell blastogeneses and DCHto oxazolone were also examined. Ubenimex increased [3H]TdR incorporation into Con A-stimulated T cell blastogenesis at 0.5 mM (Fig. 1) . OH-Ubenimex also enhanced T cell blastogenesis at the same concentration but to a lesser degree. (2S,3R)-AHPA had no effect on this blastogenesis. Neither metabolite affected LPS-stimulated B cell blastogenesis using spleen cells as the B cell preparation although ubenimex clearly enhanced this blastogenesis (data not shown). Additionally, both metabolites had practically no enhancing effect on DCH (Table 2) .
Examining the antitumor effects of OH-ubenimex and (2aS,3<R)-AHPA, we found the IC50 values of OH-ubenimex and (2*S,3iO-AHPA against in vitro growth of K562 cells were 82^g/ml and more than 200 /*g/ml, respectively, whereas the IC50 value of ubenimex was less than 12.5 //g/ml (Table 3) . Metabolites IC50 values were more than 200 jug/ml against HeLa S3 cells, whereas that of ubenimex was 108 /«g/'ml. This indicates that both metabolites have almost no direct cytotoxicity in vitro. Against IMCcarcinoma OH-ubenimexexerted in vivo antitumor effect similar to that of ubenimex but against C1498 leukemia the effect was less than that of ubenimex (Table 4) .
The acute toxicity in mice was also examined. Both metabolites did not exhibit toxicity when administered either intraperitoneally or orally at the maximumdose of 2 g/kg.
Discussion
The pharmacokinetics and biotransformation of ubenimex have been examined in detail14>20»24). Koyamareported that ubenimex was rapidly and well absorbed from the gastro-intestinal tract and then excreted mainly into urine following oral administration to rat, dog and human. When ubenimex was administered to human, relatively small amounts of two metabolites, (2*S,3jR)-AHPA and OH-ubenimexand more than 70% of unchanged ubenimex were excreted into urine20). We examined the biological activity of these two metabolites.
OH-Ubenimex, the main human metabolite of ubenimex, had APase-inhibitory activity, immunomodulatingactivity and antitumor activity. Someof these activities were similar to those of ubenimex, while some were less. Namely, the inhibitory effects of macrophage APases and IMC carcinoma growth were similar, while the enhancing effects on T and B cell blastogenesis and DCH, the inhibitory effect on C1498 leukemia and the direct cytotoxicity of tumor cells were less.
Therefore, OH-ubenimex has similar biological activity to ubenimex but was less potent. (28,3R)- DEC. 1988 AHPAlacked almost all of the activity of ubenirnex.
